PTC Therapeutics

PTC Cuts Early-Stage Pipeline but Pushes Forward on FA Drug After Phase III Flop
PTC Cuts Early-Stage Pipeline but Pushes Forward on FA Drug After Phase III Flop
BioSpace
PTC Therapeutics
Friedreich's Ataxia
clinical trials
vatiquinone
Flag link:
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics
Fierce Biotech
PTC Therapeutics
Biomarin
PKU
clinical trials
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
PTC Therapeutics CEO Stuart Peltz to retire after 25 years
PTC Therapeutics CEO Stuart Peltz to retire after 25 years
NASDAQ.com
Pharma CEOs
PTC Therapeutics
Stuart Peltz
Flag link:
Promising gene therapy delivers treatment directly to brain
Promising gene therapy delivers treatment directly to brain
Stat
gene therapy
brain
drug delivery
PTC Therapeutics
Flag link:
Huntington's Disease Continues to Baffle Biopharma
Huntington's Disease Continues to Baffle Biopharma
BioSpace
Huntington's disease
Triplet Therapeutics
PTC Therapeutics
Flag link:
Biogen, BioAge and PTC Present Novel MoAs in Neurodegenerative Diseases
Biogen, BioAge and PTC Present Novel MoAs in Neurodegenerative Diseases
BioSpace
neurodegenerative disease
Biogen
BioAge Labs
PTC Therapeutics
Flag link:
PTC Ready to Take Another Shot at FDA Approval of DMD Drug
PTC Ready to Take Another Shot at FDA Approval of DMD Drug
BioSpace
PTC Therapeutics
Translarna
FDA
Duchenne Muscular Dystrophy
Flag link:
Roche puts pressure on SMA rivals with new FDA approval
Roche puts pressure on SMA rivals with new FDA approval
Pharmaforum
Roche
PTC Therapeutics
SMA
Evrysdi
FDA
Flag link:
PTC aims again for FDA review of Duchenne drug despite latest miss
PTC aims again for FDA review of Duchenne drug despite latest miss
BioPharma Dive
PTC Therapeutics
Translarna
Duchenne Muscular Dystrophy
FDA
Flag link:
PTC Therapeutics taps experimental cancer drug for new COVID-19 trial
PTC Therapeutics taps experimental cancer drug for new COVID-19 trial
Fierce Biotech
PTC Therapeutics
clinical trials
COVID-19
PTC29
Flag link:
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
Beckers Hospital Review
OptumRx
Roche
PTC Therapeutics
risdiplam
SMA
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Immunomedics
Trodelvy
triple negative breast cancer
Flag link:
Stepping on BioMarin's turf, PTC Therapeutics picks up PKU drug for a song
Stepping on BioMarin's turf, PTC Therapeutics picks up PKU drug for a song
Endpoints
PTC Therapeutics
Censa Pharmaceuticals
PKU
M&A
Flag link:
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Reuters
gene therapy
drug manufacturing
Pfizer
Novartis
Bluebird Bio
PTC Therapeutics
Krystal Biotech
Flag link:
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Endpoints
Roche
PTC Therapeutics
SMA
risdiplam
Biogen
Spinraza
Flag link:
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis
Flag link:
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
Flag link:
Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock
Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock
Endpoints
PTC Therapeutics
gene therapy
M&A
Agilis
Flag link:

Pages